Sanreno Therapeutics Announces Acquisition By Novartis In Pivotal Transaction To Bring Forward Transformative Therapeutics In Kidney Disease
Acquiring Company
Novartis
Acquired Company
SanReno Therapeutics
Switzerland
ShanghaiBiotechnologyHealth CarepharmaceuticalsBiotechnology ResearchDescription
SanReno Therapeutics, a clinical-stage company specializing in the discovery, development, and commercialization of innovative therapies for kidney diseases, today announces its acquisition by Novartis, a global medicines company. Following the acquisition's closure, SanReno becomes an indirect, wholly-owned subsidiary of Novartis. The founding investors of SanReno, including Pivotal bioVenture Partners China, Frazier Life Sciences, Samsara BioCapital, and Versant Ventures, have sold their equity securities in SanReno.
Other recent acquisitions in pharmaceuticals and Biotechnology Research
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right (February 16, 2024)
- Novo Holdings to Acquire Catalent (February 5, 2024)
- Myriad Genetics to Acquire Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics (January 18, 2024)
- Avista Capital Partners Acquires Terrats Medical from Miura Partners (February 16, 2024)
- Petauri™ Acquires FORCE Communications (February 14, 2024)
- Immunome to Acquire AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals (February 6, 2024)
Who to call at Novartis, and when
When Novartis changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Novartis raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Novartis, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Novartis. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Novartis makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired SanReno Therapeutics?
SanReno Therapeutics was acquired by Novartis, based in Switzerland. The deal was reported on January 5, 2024. Novartis AG is a Swiss multinational pharmaceutical company headquartered in Basel. Novartis is publicly traded (NVS) and operates in Biotechnology.
When did Novartis acquire SanReno Therapeutics?
Novartis's acquisition of SanReno Therapeutics was reported on January 5, 2024. SanReno Therapeutics, a clinical-stage company specializing in the discovery, development, and commercialization of innovative therapies for kidney diseases, today announces its acquisition by Novartis, a global medicines company. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does SanReno Therapeutics do?
Founded in December 2021, SanReno Therapeutics is a clinical-stage biotech focused on kidney diseases and related therapeutic areas. It is privately held, operating in Biotechnology Research, and is based in Shanghai.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.